natgillin/translations-raw huggingface dataset:
The CHMP concluded that, in accordance with EU requirements, Olanzapine Apotex has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Olanzapine Apotex primerljivo raven kakovosti kot zdravili Zxprexa in Zyprexa Velotab ter da jima je biološko enakovredno.
Other information about Olanzapine Apotex:
Druge informacije o zdravilu Olanzapine Apotex:
The Committee recommended that Olanzapine Apotex be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Olanzapine Apotex odobri dovoljenje za promet.
The active substance in Olanzapine Apotex, olanzapine, is an antipsychotic medicine.
Zdravilna učinkovina zdravila Olanzapine Apotex, olanzapin, je antipsihotično zdravilo.
The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Apotex to Apotex Europe B.V. on 10 June 2010.
Evropska komisija je dovoljenje za promet z zdravilom Olanzapine Apotex, veljavno po vsej Evropski uniji, odobrila družbi Apotex Europe B.V.
What are the benefit and risk of Olanzapine Apotex?
Kakšne so koristi in tveganja, povezani z zdravilom Olanzapine Apotex?
The orodispersible tablets are taken by being placed on the tongue, where they disintegrate in the saliva, or by mixing them in water before swallowing.
Razpon odmerkov je običajno od 5 do 20 mg na dan. Orodisperzibilne tablete se zaužije tako, da se položijo na jezik, kjer jih slina raztopi, ali tako, da se pred zaužitjem zmešajo z vodo.
Olanzapine Apotex is a ‘generic medicine'.
Zdravilo Olanzapine Apotex je „generično zdravilo“.
Olanzapine Apotex is a medicine containing the active substance olanzapine.
Olanzapine Apotex je zdravilo, ki vsebuje zdravilno učinkovino olanzapin.
Olanzapine Apotex is used to treat adults with schizophrenia.
Zdravilo Olanzapine Apotex se uporablja za zdravljenje shizofrenije.
Why has Olanzapine Apotex been approved?
Zakaj je bilo zdravilo Olanzapine Apotex odobreno?
The full EPAR for Olanzapine Apotex can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Olanzapine Apotex je na voljo tukaj.
What is Olanzapine Apotex?
Kaj je zdravilo Olanzapine Apotex?
How has Olanzapine Apotex been studied?
Kako je bilo zdravilo Olanzapine Apotex raziskano?
What is Olanzapine Apotex used for?
Za kaj se zdravilo Olanzapine Apotex uporablja?
How does Olanzapine Apotex work?
Kako zdravilo Olanzapine Apotex deluje?
How is Olanzapine Apotex used?
Kako se zdravilo Olanzapine Apotex uporablja?
United Kingdom Clinigen Healthcare Ltd. Pitcairn House, Crown Square First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW
Velika Britanija Clinigen Healthcare Ltd. Pitcairn House, Crown Square First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW, Velika Britanija
Annex I List of medicinal products and presentations
Priloga I Seznam zdravil in njihovi farmacevtskih oblik ter jakosti
These occur in more than 1 in 10 people.
Ti učinki so se pojavili pri več kot 1 osebi od 10.
Ocrevus is used in two types of patients:
Zdravilo Ocrevus se uporablja pri dveh vrstah bolnikov:
The first two infusions are given two weeks apart and subsequent infusions are given every six months.
Prvi dve infuziji je treba dati v razmiku dveh tednov, nadaljnje infuzije pa vsakih šest mesecev.
What measures are being taken to ensure the safe and effective use of Ocrevus?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ocrevus?
The full EPAR for Ocrevus can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ocrevus je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Ocrevus must not be used in patients with active infections or severely weakened immune systems or in patients with cancer.
Zdravilo Ocrevus se ne sme uporabljati pri bolnikih z aktivnimi okužbami ali močno oslabljenim imunskim sistemom ali pri bolnikih z rakom.
followed by periods with milder or no symptoms;
(recidive), ki jim sledijo obdobja z blažjimi simptomi ali brez simptomov;
Before each infusion, the patient is given other medicines (a corticosteroid and an antihistamine) to help to prevent potentially dangerous reactions.
Bolnik pred vsako infuzijo prejme drugi zdravili (kortikosteroid in antihistaminik), ki pomagata preprečevati morebitne nevarne reakcije.
If reactions occur during an infusion it may be stopped or given more slowly.
Če pride med infundiranjem do reakcij, se infuzija lahko ustavi ali daje počasneje.
This is a summary of the European public assessment report (EPAR) for Ocrevus.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ocrevus.
Other information about Ocrevus
Druge informacije o zdravilu Ocrevus
What benefits of Ocrevus have been shown in studies?
Kakšne koristi je zdravilo Ocrevus izkazalo v študijah?
What is Ocrevus and what is it used for?
Kaj je zdravilo Ocrevus in za kaj se uporablja?
It is not intended to provide practical advice on how to use Ocrevus.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The patient should be monitored during the infusion and for at least an hour afterwards, and facilities to manage severe reactions should be readily available.
Bolnika je treba med infundiranjem in še vsaj eno uro po tem spremljati, na voljo pa mora biti oprema za ukrepanje v primeru hudih reakcij.
The active substance in Ocrevus, ocrelizumab, is a monoclonal antibody designed to recognise and attach to a target called CD20 on the surface of certain types of white blood cells (so called B cells).
Zdravilna učinkovina v zdravilu Ocrevus, okrelizumab, je monoklonsko protitelo, ki je bilo zasnovano tako, da prepozna tarčno beljakovino, imenovano CD20, ki je prisotna na površini nekaterih vrst belih krvnih celic (t. i. celic B), in se veže nanjo.
What are the risks associated with Ocrevus?
Kakšna tveganja so povezana z zdravilom Ocrevus?
The European Medicines Agency concluded that the benefits seen with Ocrevus outweighed its risks and recommended that it be authorised in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Ocrevus večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
A third study, in 732 patients with primary progressive multiple sclerosis (PPMS), showed that fewer patients taking Ocrevus had worsening symptoms lasting 12 weeks or more (30%) compared with those taking a placebo (34%).
Tretja študija pri 732 bolnikih s primarno progresivno multiplo sklerozo (PPMS) je pokazala, da je do poslabšanja simptomov, ki je trajalo 12 tednov ali več, prišlo pri manj bolnikih, ki so jemali zdravilo Ocrevus (30 %), kot pri tistih, ki so jemali placebo (34 %).
Ocrevus treatment also provided some benefit in patients with primary progressive multiple sclerosis, a condition for which treatments are urgently needed.
Zdravljenje z zdravilom Ocrevus je nekoliko koristilo tudi bolnikom s primarno progresivno multiplo sklerozo, boleznijo, za katero so zdravila nujno potrebna.
In two studies of 1,656 patients with relapsing forms of multiple sclerosis (RMS), the average number of relapses in patients treated with Ocrevus was about half that in patients treated with another medicine interferon beta-1a (0.16 versus 0.29 relapses per year).
V dveh študijah, ki sta vključevali 1 656 bolnikov z recidivnimi oblikami multiple skleroze (RMS), je bilo povprečno število recidivov pri bolnikih, zdravljenih z zdravilom Ocrevus, enako približno polovici števila recidivov pri bolnikih, zdravljenih z drugim zdravilom, interferonom beta-1a (0,16 v primerjavi z 0,29 recidiva na leto).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ocrevus have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ocrevus upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
These white blood cells play a role in multiple sclerosis by attacking the sheaths around the nerves in the brain and spinal cord, causing inflammation and damage.
Te bele krvne celice sodelujejo pri multipli sklerozi tako, da napadajo ovojnice okrog živcev v možganih in hrbtenjači, s čimer povzročajo vnetje in poškodbo.
For more information about treatment with Ocrevus, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Ocrevus preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
• adults with primary progressive multiple sclerosis (PPMS), where symptoms get steadily worse over time.
• pri odraslih s primarno progresivno multiplo sklerozo (PPMS), pri kateri se simptomi stalno slabšajo.
Why is Ocrevus approved?
Zakaj je bilo zdravilo Ocrevus odobreno?
Studies have shown that Ocrevus is effective at reducing the number of relapses and it can also reduce the worsening of symptoms in some patients.
Študije so pokazale, da zdravilo Ocrevus učinkovito zmanjšuje število recidivov in lahko pri nekaterih bolnikih tudi upočasni slabšanje simptomov.
By targeting the B cells, Ocrevus helps to reduce their activity and thereby relieves symptoms or slows down the worsening of the disease.
Zdravilo Ocrevus z usmerjanjem na celice B pomaga zmanjševati njihovo dejavnost in s tem blaži simptome ali upočasnjuje slabšanje bolezni.
Ocrevus can only be obtained with a prescription and treatment must only be started and supervised by a doctor experienced in treating diseases of the nerves.
Predpisovanje in izdaja zdravila Ocrevus je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolezni živčevja.
The most important and most frequently reported side effects with Ocrevus are infusion reactions (such as itching, rash, and difficulty breathing) and infections.
Najpomembnejši neželeni učinki zdravila Ocrevus, o katerih so najpogosteje poročali, so reakcije na infundiranje (srbenje, izpuščaj in težave z dihanjem) in okužbe.
Ocrevus is a medicine for treating multiple sclerosis - an inflammatory disease of the nervous system that causes symptoms such as weakness, difficulty walking and problems with vision.
Zdravilo Ocrevus se uporablja za zdravljenje multiple skleroze, tj. vnetnega obolenja živčevja, ki povzroča simptome, kot so šibkost, težave s hojo in težave z vidom.
For practical information about using Ocrevus, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Ocrevus naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
• adults with relapsing forms of multiple sclerosis (RMS), where the patient has flare-ups (relapses)
• pri odraslih z recidivnimi oblikami multiple skleroze (RMS), pri čemer ima bolnik poslabšanja
Ocrevus is given as an infusion (drip) into a vein.
Zdravilo Ocrevus se daje z infundiranjem (kapalno infuzijo) v veno.
How does Ocrevus work?
Kako zdravilo Ocrevus deluje?
For the full list of side effects reported with Ocrevus, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ocrevus, glejte navodilo za uporabo.
Studies showed that Ocrevus was more effective than interferon beta-1a at reducing the number of relapses in patients with relapsing forms of multiple sclerosis.
Študije so pokazale, da je bilo zdravilo Ocrevus pri zmanjševanju števila recidivov pri bolnikih z recidivnimi oblikami multiple skleroze učinkovitejše od interferona beta-1a.
How is Ocrevus used?
Kako se zdravilo Ocrevus uporablja?
Ocrevus contains the active substance ocrelizumab.
Zdravilo Ocrevus vsebuje zdravilno učinkovino okrelizumab.
Date of first authorisation: 28 April 2004 Date of last renewal: 28 April 2009
Datum prve odobritve: 28. april 2004 Datum zadnjega podaljšanja : 28. april 2009
Older patients (≥ 65 years old)
Starejši bolniki (≥ 65 let)
Safety data are based on literature (mainly retrospective studies).
Podatki o varnosti temeljijo na literaturi (večinoma retrospektivne študije).
Do not take a double dose to make up for the forgotten one.
Ne vzemite dvojnega odmerka, da nadomestite pozabljenega.
After opening: 1 year.
Po odprtju: 1 leto.
• Risk management plan (RMP)
Načrt za obvladovanje tveganja (RMP)
These symptoms may reveal complications for which specific medication could be appropriate.
Ti simptomi lahko razkrijejo zaplete, za katere so lahko ustrezna določena zdravila.
Lysodren").
Lysorden«).
Other effects should be treated symptomatically.
Drugi učinki se zdravijo simptomatično.
Treatment should be initiated and followed by a suitably experienced specialist.
Zdravljenje naj uvede in spremlja primerno izkušen zdravnik.
EXP After opening: 1 year
EXP: Po odprtju: 1 leto.
Nervous system undesirable effects occur in approximately 40 % of patients.
Neželeni učinki na živčevje se pojavijo pri približno 40 % bolnikov.
Leucopoenia has been reported in 8 to 12 % of patients.
O levkopeniji so poročali pri 8 do 12 % bolnikov.
France Tel: + 33 1 40 33 93 14
Tel: + 33 1 40 33 93 14 Izdelovalec
There were recurrences in 40% of children; the survival rate at 5 years was 49%.
Bolezen se je ponovno pojavila pri 40 % otrok, petletno preživetje je bilo 49 %.
The target plasma concentration is usually reached within a period of 3 to 5 months.
Ciljna plazemska koncentracija se ponavadi doseže v 3 do 5 mesecih.
Hypothyroidism and growth retardation may be also observed.
Opaziti je mogoče tudi hipotiroidizem in zaostalost v rasti.
UNIQUE IDENTIFIER - 2D BARCODE
ENOLIČNA IDENTIFIKACIJSKA OZNAKA - 2D ČRTNA KODA
More than 80 % of patients treated with mitotane have shown at least one type of undesirable effect.
Več kot 80 % bolnikov zdravljenih z mitotanom je imelo vsaj eno vrsto neželenih učinkov.
For further information on the sample testing please contact the Marketing Authorisation Holder or its local representative (see section 7).
Za dodatne informacije o testiranju vzorcev se obrnite na imetnika dovoljenja za promet z zdravilom ali njegovega lokalnega predstavnika (glejte poglavje 7).
However, this result should be cautiously taken since the examination of the mitotane effects was not the primary endpoint of the study.
Vendar je treba ta rezultat obravnavati previdno, saj raziskovanje učinkov mitotana ni bil primarni opazovani dogodek v študiji.
Mitotane has not been studied in a comprehensive clinical development program.
Mitotana niso preučevali v obsežnem programu kliničnega razvoja.
They are bisected on one side and impressed "BL" over "L1" on the other side.
Na eni strani imajo zarezo, na drugi pa vtisnjen napis »BL« nad »L1«.
2.800 04010 Sermoneta (Latina) Italy or
04010 Sermoneta (Latina) Italija ali
Therefore, steroid replacement may be necessary in these patients.
Pri teh bolnikih bo morda potrebna nadomestitev steroidov.
Frequency Not Known
Pogostnost ni znana
Ambulatory patients should be warned not to drive or use machines.
Bolnike, ki se zdravijo ambulantno, je treba opozoriti, naj ne vozijo in ne upravljajo strojev.
Autoimmune hepatitis has been reported in 7 % of patients with no other information on mechanism.
O avtoimunskem hepatitisu so poročali pri 7 % bolnikov brez dodatnih podatkov o mehanizmu.
Microcrystalline cellulose (E 460) Macrogol 3350
Mikrokristalna celuloza (E 460) Makrogol 3350
Frequency groupings are defined according to the following convention: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from the available data).
Pogostnost je opredeljena na naslednji način: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of the medicine.
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
Table 1: Frequency of adverse reactions identified from literature data
Tabela 1: Pogostnost neželenih reakcij, navedenih v podatkih iz literature Neželena reakcija
Some of these effects (anorexia) may constitute the hallmark of initial central nervous system impairment.
Nekateri učinki (anoreksija) predstavljajo začetne znake motenj centralnega živčnega sistema.
Skin rashes which have been reported in 5 to 25 % of patients do not seem to be dose related.
Videti je, da izpuščaji na koži, o katerih so poročali pri 5 do 25 % bolnikov, niso odvisni od odmerka.
UNIQUE IDENTIFIER - HUMAN READABLE DATA
ENOLIČNA IDENTIFIKACIJSKA OZNAKA - ČLOVEKU BERLJIVI PODATKI
Paediatric patients
Pediatrični bolniki
Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Animal studies with similar substances have shown reproductive toxicity (see section 5.3).
V študijah na živalih s podobnimi snovmi so odkrili reproduktivno toksičnost (glejte poglavje 5.3).
If no clinical benefits are observed after 3 months at optimal dose, treatment should be permanently discontinued.
Če kliničnih koristi ni opaziti po 3 mesecih optimalnega odmerjanja, je treba z zdravljenjem trajno prekiniti.
Overall, the disease-free interval was 7 months (2 to 16 months).
V povprečju je bil čas brez bolezni 7 mesecev (2 do 16
Pharmacotherapeutic group: Other antineoplastic agents, ATC code: L01XX23
Farmakoterapevtska skupina: druga zdravila z delovanjem na novotvorbe, oznaka ATC: L01XX23
Therefore, you should tell your doctor if you are using medicines containing any of the following active substances: - warfarin or other anticoagulants (blood thinners), used to prevent blood clots.
Zato morate povedati zdravniku, če uporabljate zdravila, ki vsebujejo katerekoli izmed naslednjih zdravilnih učinkovin: - varfarin in drugi antikoagulanti (zdravila za redčenje krvi), ki se uporabljajo za preprečevanje krvnih strdkov.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov izdelovalca, odgovornega za sprostitev zadevne serije.
Gastrointestinal disorders are the most frequently reported (10 to 100 % of patients) and are reversible when the dose is reduced.
Bolezni prebavil so najpogosteje poročane (pri 10 do 100 % bolnikov) in so reverzibilne, ko se odmerek zmanjša.
This should be taken into account when interpreting the results of hormonal assays and may result in gynaecomastia.
To je treba upoštevati pri interpretaciji rezultatov hormonskih preiskav, lahko pa tudi povzroči ginekomastijo.
Dose adjustments, monitoring and discontinuation
Prilagajanje, nadzorovanje in prekinitev odmerjanja
Opportunistic mycosis
Oportunistična mikoza
After intravenous administration, 25% of the dose was excreted as metabolites within 24 hours.
Po intravenskem dajanju se 25 % odmerka izloči v obliki presnovkov v 24 urah.
You can divide the total daily dose in two or three intakes.
Skupni dnevni odmerek lahko razdelite v dva ali tri odmerke.
Consequently, despite a constant dose, mitotane levels may increase.
Posledično se kljub stalnemu odmerku koncentracija mitotana lahko zviša.
Mitotane plasma levels higher than 20 mg/l may be associated with severe undesirable effects and offer no further benefit in terms of efficacy.
Plazemske koncentracije mitotana višje od 20 mg/l so mogoče povezane s hudimi neželenimi učinki in ne prinašajo koristi v smislu učinkovitosti.
The activity of liver enzymes (gamma-GT, aminotransferase, alkaline phosphatase) is commonly increased.
Aktivnosti jetrnih encimov (gama-GT, aminotransferaza, alkalna fosfataza) so običajno povečane.
A case of cholestatic hepatitis has been reported.
Poročali so o primeru holestatskega hepatitisa.
The experience in patients in this age group is very limited.
Izkušenj z bolniki v tej starostni skupini je malo.
After six months mitotane plasma levels were undetectable and the patient recovered clinically.
Po šestih mesecih ravni mitotana v plazmi ni bilo mogoče zaznati in bolnik je klinično okreval.
Mitotane apparently causes increased formation of 6-betahydroxy cholesterol.
Očitno mitotan povzroči povečano tvorbo 6-beta-hidroksiholesterola.
Because of an increased risk of acute adrenocortical insufficiency, patients should be instructed to contact their physician immediately if injury, infection, or any other concomitant illness occurs.
Zaradi povečanega tveganja akutne adrenokortikalne insuficience, je potrebno bolnikom svetovati, da takoj obvestijo svojega zdravnika v primerih poškodbe, okužbe ali katerekoli sočasne druge bolezni.
If you accidentally miss a dose, just take the next dose as scheduled.
Če pomotoma izpustite odmerek, vzemite naslednji odmerek po običajnem urniku.
The dose of your anticoagulant may need adjustment.
Odmerek antikoagulanta bo morda treba prilagoditi;
Psychiatric disorders Confusion
Psihiatrične motnje Zmedenost
Paediatric patients The experience in children is limited.
Pediatrična populacija Izkušenj pri otrocih je malo.
Liver enzymes levels normalize when the mitotane dose is decreased.
Vrednost jetrnih encimov se normalizira, ko se odmerek mitotana zmanjša.
For information on the product, please contact:
Za informacije o zdravilu se obrnite na:
Liver function tests (alanine transaminase [ALT], aspartate transaminase [AST], bilirubin levels) should be periodically monitored, especially during the first months of treatment or when it is necessary to increase the dose.
Redno je treba opravljati teste delovanja jeter (ravni alanin-transaminaze [ALT], aspartat-transaminaze [AST] in bilirubina), zlasti v prvih mesecih zdravljenja ali kadar je treba povečati odmerek.
Always keep with you the Lysodren Patient Card included at the end of this leaflet.
Vedno imejte pri sebi izkaznico bolnika za zdravilo Lysodren, ki je priložena na koncu tega navodila.
The usual starting dose for adults is 2 to 3 g (4 to 6 tablets) per day.
Običajni začetni odmerek za odrasle je 2 do 3 g (4 do 6 tablet) na dan.
The name of my Doctor is: Phone: ……………………………….
Tel. številka: ……………………………….
Risk of adrenal insufficiency: All patients with non functional tumour and 75% of patients with functional tumour show signs of adrenal insufficiency.
Tveganje za oslabljeno delovanje nadledvične žleze: Vsi bolniki z nefunkcionalnim tumorjem in 75 % bolnikov s funkcionalnim tumorjem kažejo znake oslabljenega delovanja nadledvične žleze.
Due to the prolonged half-life, significant serum concentrations may persist for weeks after cessation of therapy.
Zaradi podaljšanega razpolovnega časa lahko znatne koncentracije v serumu vztrajajo več tednov po koncu zdravljenja.
Use in children and adolescents The starting daily dose of Lysodren is 1.5 to 3.5 g/m2 body surface (this will be calculated by your doctor according to the weight and the size of the child).
Uporaba pri otrocih in mladostnikih Začetni dnevni odmerek zdravila Lysodren je 1,5 do 3,5 g/m telesne površine (zdravnik jo bo izračunal na podlagi teže in velikosti otroka).
Lysodren is available in plastic bottles of 100 tablets.
Zdravilo Lysodren je na voljo v plastičnih steklenicah s 100 tabletami.
There was a positive linear correlation between the cumulative dose of Lysodren and the plasma levels of mitotane.
Obstajala je pozitivna linearna korelacija med kumulativnim odmerkom Lysodrena in plazemskimi koncentracijami mitotana.